General Announcement::Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
29-Apr-2020 13:21:42
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets
Announcement Reference
SG200429OTHR1Q35
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
29/04/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg

Attachments

SGX_PR_29042020.pdf
Total size =1325K